Eli Lilly & Co (LLY) DIvidends Date & History

Key Takeaways

• Eli Lilly and Company pays a quarterly dividend of $1.73 per share, translating to an annualized dividend of $6.92 and a current dividend yield of approximately 0.57%.
• The company has raised its dividend for 11 consecutive years, with annual dividend increases averaging roughly 15% over the past several years.
• The dividend payout ratio stands at approximately 24% to 28% of earnings, indicating strong earnings coverage and significant room for future increases.
• Despite the low headline yield, the combination of rapid dividend growth and a conservative payout ratio makes LLY an underappreciated name among dividend growth investors.
• The next ex-dividend date is August 14, 2026, with a payment date of September 10, 2026.

Dividend Overview

LLY is not a high-yield stock by any conventional measure. With a dividend yield hovering around 0.57%, Eli Lilly falls well below the healthcare sector average of approximately 1.66%. However, the company is firmly established as a dividend growth stock. Eli Lilly has paid dividends to shareholders for decades — its dividend history stretches back to the 1970s and earlier — and the current quarterly rate of $1.73 per share reflects a 15.2% increase from the $1.50 paid throughout 2025. The dividend is distributed on a quarterly schedule, with payments typically occurring in March, June, September, and December. For income-oriented investors, LLY's dividend profile is best understood not as a source of current income, but as a growing return that compounds meaningfully over time thanks to the company's robust earnings trajectory.

Dividend History and Growth

Eli Lilly's dividend growth story has been remarkably consistent in recent years. Annual dividend per share has risen from $3.40 in 2021 to $3.92 in 2022, $4.52 in 2023, $5.20 in 2024, $6.00 in 2025, and now stands at an annualized $6.92 following the 2026 increase to $1.73 per quarter. Each of these annual steps represents approximately a 15% year-over-year increase. According to data from the company's investor relations page, Eli Lilly has now recorded 11 consecutive years of dividend growth. The company last maintained a flat dividend during the 2013–2014 period before resuming its upward trajectory in 2015. As of 2026, the quarterly dividend is more than double what it was just five years ago — a testament to Lilly's rapid earnings expansion, driven by blockbuster products in diabetes, obesity, and immunology.

Dividend Sustainability and Payout Ratio

The sustainability of Eli Lilly's dividend appears exceptionally strong. The trailing payout ratio — the percentage of earnings paid out as dividends — sits between approximately 24% and 28%, depending on the specific earnings metric used. This means Eli Lilly retains more than 70% of its profits for reinvestment in research and development, manufacturing expansion, and strategic acquisitions. The company's free cash flow, reported at approximately $1.4 billion, provides an additional layer of coverage. While Lilly carries a debt-to-equity ratio of approximately 1.86 — elevated due to financing for recent capacity expansions — its net profit margin of roughly 26% and return on equity (ROE) exceeding 90% underscore its financial firepower. The low payout ratio, combined with double-digit earnings growth, suggests the dividend is not only secure but has substantial headroom for continued increases.

Dividend Compared to Industry Peers

Within the pharmaceutical industry, dividend profiles vary widely. Large-cap peers such as JNJ (Johnson & Johnson) and PFE (Pfizer) offer dividend yields in the 2.5% to 6% range, while MRK (Merck) yields roughly 2.5% to 3%. Against this backdrop, LLY's 0.57% yield appears modest. However, the comparison shifts favorably when examining dividend growth. Lilly's 15% annual dividend growth rate far outpaces the single-digit increases typical of most large pharmaceutical peers. The company's low payout ratio also distinguishes it — many pharma peers operate with payout ratios between 40% and 100% of earnings, leaving less room for future growth. For investors willing to trade current yield for future income growth, LLY's dividend profile stands apart from the industry norm.

AI Screener

Discovering dividend stocks with both growth potential and financial stability can be time-consuming when relying on manual research alone. Tickeron's AI Screener addresses this challenge by offering an AI-powered stock and ETF discovery tool that enables traders and investors to filter the market using a broad range of criteria, including technical patterns, fundamental metrics, volatility profiles, and AI-driven trading signals. Users can scan thousands of stocks and ETFs by applying customizable filters such as industry classification, market capitalization, dividend yield, payout ratios, and performance indicators. For those focused on income-generating investments, the screener helps identify dividend stocks, breakout candidates, and emerging market opportunities far more efficiently than traditional manual screening. Explore the AI Screener today to streamline your search for your next investment idea.

Is This Stock Attractive for Dividend Investors?

Eli Lilly and Company is best suited for dividend growth investors and long-term total-return investors rather than those seeking high current income. With a yield below 1%, LLY will not satisfy the needs of income-dependent investors who rely on regular portfolio distributions to meet living expenses. However, for investors with a time horizon of five to ten years or more, the stock offers a compelling proposition: a rapidly growing dividend supported by extraordinary earnings momentum and a conservative payout ratio. The company's 11-year dividend growth streak, 15% annual increases, and payout ratio below 30% collectively suggest that dividend growth can continue at an above-average pace for the foreseeable future. Conservative investors should, however, weigh the elevated valuation — reflected in a price-to-earnings (P/E) ratio above 50 — and the company's leveraged balance sheet against its strong operational performance. Overall, LLY functions as a dividend growth holding within a diversified portfolio, where its modest current yield is offset by a powerful long-term compounding trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations